Medical articles today

/* 728x15, */

AFFiRiS AG: Atherosclerosis Vaccine Elaborating Receives EU Back

/* 468x60, */

The atherosclerosis vaccine buildup programme by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is career carried gone in cooperation with German society EMC microcollections GmbH. The site of atherosclerosis vaccination is to increase the vastness of "good" eminent density lipoprotein cholesterol (HDLc) in the blood and thus reduce the adventure of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS' AFFITOME(R) platform technology. The entity is a protein hackneyed as CETP (cholesteryl ester transfer protein). Following vaccines for Alzheimer's disease and Parkinson's disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.
Vienna-based AFFiRiS AG nowadays announced that its atherosclerosis vaccine development program is receiving assist from the EU's EUROTRANS-BIO call. The supported project - known as CETP Vaccine (ETB-2008-28) - is based on the AFFITOME(R) technology of AFFiRiS AG and is being conducted cool with EMC microcollections GmbH from Tubingen, Germany. The pressing need for an effective strategy against atherosclerosis is clearly evident from the relevant figures - diseases of the cardiovascular process are the number one cause of death in Europe and the US. In Europe, this is at the root of nearly 50 % of all deaths. One of the meaningful causes of cardiovascular disease is atherosclerosis, a narrowing of key arteries due to fatty deposits. Although there are options for medication-based intervention in the appearance of statins, these are deemed to be of local effectiveness in spite of some notable successes.
CSO Dr. Frank Mattner explains: "Today's therapies with Statins reality on low density lipoprotein cholesterol (LDLc) and incision its concentration in the blood. This type of treatment can lower the likelihood of severe passion disease by as immature as 30 % - and that's one shot if the patient takes the essential medication correctly and regularly. In contrast, our vaccine advance aims at decreasing the cholesterol transfer from HDL to LDL, thus increasing the concentration of the beneficial HDL. This vaccine nearing with its long-lasting effects should avoid patients having to catch life-long, daily medication to a strict regimen."
The leading object of the seam efforts of AFFiRiS and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good" HDL and has a detrimental impulse on the ratio of LDLc to HDLc. In the future, our vaccine testament lessen the motion of this protein and shift the balance of HDLc and LDLc in the blood back in favor of HDLc.
Outlining the major benefit of the AFFITOME(R) technology, project chief Dr. Sylvia Brunner adds: "CETP is one of the body's own proteins. Trying to dilute its hustle using a vaccine, we are faced with a formidable challenge. The reason has divers means of suppressing an resistant response to its own proteins, or limiting the effectiveness of any such response. That's why preceding attempts to evolve a vaccine against CETP failed. However, as AFFiRiS has already demonstrated in its donkeywork on a vaccine for Alzheimer's disease, the AFFITOME(R) technology makes it possible to circumvent these mechanisms. We are now applying this rule to atherosclerosis."
CEO Dr. Walter Schmidt continues: "So far, we obtain announced the process of vaccines for three diseases - Alzheimer's, Parkinson's and first off atherosclerosis. Currently, four other indications are besides any of our evolving pipeline, all of them characterised by a very flying quantity of patients but also by a default of satisfactory treatments. As a result, these indications fit in well with our long-term strategy. Our strategy itself is dawn to pament back as demonstrated by the licensing agreement cost EUR 430 million that we recently concluded with GSK Biologicals regarding the rights for the technology for our Alzheimer's vaccine programs."
The CETP Vaccine project is scheduled to behind 30 months and is due to culminate in phase I clinical trials. Overall, the advice if to the project by the EU is valuation several hundred thousand euros, while the two project partners are bearing encompassing half of the total costs.
About AFFiRiS AG (as at May 2009):
AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical concept and for which the market volumes are highly attractive. Alzheimer's disease is currently the foremost comment and two possible products are in the ending stages of clinical folio I studies. In Oct 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The business agreement foresees payments of up to EUR 430 million (these payments are dependent on firm milestones). AFFiRiS currently employs 50 highly-qualified staff and recently acquired an additional 1,100 square meters of premises at the St. Marx campus in Vienna, Austria.
Source: AFFiRiS AG
/* 468x60, */


vaccine, atherosclerosis vaccine, vaccine elaborating, vaccine project, cetp vaccine, vaccine nearing, vaccine faced, vaccine buildup, vaccine business, vaccine development
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy